$QMCO

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Quantum, Unicycive, Fly-E, and Lantheus on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Fly-E Group (NASDAQ:FLYE), Lantheus Holdings (NASDAQ:LNTH)

NEW YORK, Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors Quantum Corporation ( NASDAQ:QMCO ) , Unicycive Therapeutics, Inc. ( NASDAQ:UNCY ) , Fly-E Group, Inc. ( NASDAQ:FLYE ) , ...

Original reporting
Benzinga · Globe Newswire
Published Nov 13, 2025, 10:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 13, 2025, 11:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Quantum, Unicycive, Fly-E, and Lantheus on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Fly-E Group (NASDAQ:FLYE), Lantheus Holdings (NASDAQ:LNTH) — source image
Decision brief

The 30-second read

$QMCONeutralLow
01

Why it matters

Legal investigations often introduce short-term uncertainty, possibly leading to stock price declines. The actual impact depends on the investigation's findings and market perception.

02

Market read

The investigation primarily impacts companies involved and may influence related sectors, with limited broader market effects.

03

What to watch

Potential positive developments or disclosures during the investigation could mitigate negative impacts and present buying opportunities.

Timing: Immediate to short-term

Background

Bragar Eagel & Squire, a shareholder rights law firm, is investigating certain officers and directors of multiple companies, including Fly-E Group and Lantheus Holdings, for potential misconduct.

Company-level read

Ticker impact

$QMCONeutralMedium confidence
Context

High relevance due to investigation involving officers and directors, potential impact on company governance and stock price.

Expected impact

Moderate negative impact in the short term, with potential recovery if investigation results are favorable.

Evidence & confidence

Legal investigations can cause short-term uncertainty; however, the long-term impact depends on the investigation's outcome.

$UNCYNeutralHigh confidence
Context

Moderate relevance; the news does not directly involve Unicycive Therapeutics but is part of broader market topics.

Expected impact

Negligible impact.

Evidence & confidence

Lack of direct connection reduces the likelihood of significant price movement.

$FLYENeutralMedium confidence
Context

High relevance; the investigation involves Fly-E Group, potentially affecting investor confidence and stock performance.

Expected impact

Possible 5-10% decrease in stock price in the near term if negative findings are released.

Evidence & confidence

Legal investigations can cause volatility; the actual impact depends on the findings and market perception.

$LNTHNeutralHigh confidence
Context

Low relevance; the news does not involve Lantheus Holdings directly.

Expected impact

Negligible.

Evidence & confidence

No direct connection diminishes potential impact.

Market effects

Potential negative sentiment in the life sciences and technology sectors due to corporate governance concerns.

Limited regional impact; primarily affects US-listed companies involved.

Minimal global impact; specific to US markets and companies involved.

Counterpoint

Legal investigations can be a temporary distraction; if findings exonerate the companies, stock prices may recover quickly.

Key entities

  • Bragar Eagel & Squire

    A nationally recognized shareholder rights law firm conducting investigations.

  • Fly-E Group

    Subject of investigation, potentially affecting stock performance.

  • Lantheus Holdings

    Unrelated to current investigation but part of the broader market context.

Related articles

$LNTHMed

Lantheus (NASDAQ:LNTH) Reports Upbeat Q2 CY2026

Lantheus Holdings (NASDAQ: LNTH) reported Q2 CY2026 revenue of $388.2 million, up 2.7% year on year, ahead of Wall Street expectations. Non-GAAP adjusted EPS was $1.55, 18.9% above consensus. The article also cites adjusted operating margin of 31% and analyst expectations for revenue to decline 3.2% and full-year EPS to fall from $5.95 to $5.55.

$LNTHHighAI 10/10

Lantheus Holdings, Inc. (LNTH): Results of Operations and Financial Condition

Lantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lnth-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Lantheus Reports Second Quarter 2026 Financial Results • Worldwide revenue of $388.2 million in the second quarter of 2026 • GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025 • Ad

$LNTHHighAI 9/10

Curium to buy Lantheus in all

Curium US will buy all outstanding shares of Nasdaq-listed Lantheus for $102.50 per share at closing, plus non-transferable CVRs worth up to $12.00 more if 2030 milestones are met, for up to $114.50 total. The offer is a 38% premium to Lantheus’ 60-day VWAP. Board approved unanimously; deal expected to close in H1 2027.

$LNTHMed

TD Cowen downgrades Lantheus stock to hold on Curium deal view

TD Cowen downgraded Lantheus Holdings (LNTH) to Hold from Buy and cut its price target to $102.50 from $110.00. Analyst Tara Bancroft said the Curium deal is fair and sees >50% odds of most contingent value milestones, but less optimism on the top PSMA PET tier. The stock trades near $102.03. Separately, the FDA issued a Complete Response Letter for LNTH-2501.

$LNTHHighAI 9/10

Lantheus Holdings To Be Acquired By Curium For Up To $8 Bln

Lantheus (LNTH) said it agreed to be acquired by Curium, backed by CapVest, for up to $8 billion. Curium US will buy all LNTH shares for $102.50 cash plus non-transferable Contingent Value Rights up to $12 per share tied to milestones through 2030. Total up to $114.50 per share, a 38% premium. Deal expected to close in 1H 2027.